Skip to main content

NASDAQ:BNR - Burning Rock Biotech Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $32.30
  • Forecasted Upside: 23.75 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$26.10
▼ -1.06 (-3.90%)
1 month | 3 months | 12 months
Get New Burning Rock Biotech Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BNR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BNR

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$32.30
▲ +23.75% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Burning Rock Biotech in the last 3 months. The average price target is $32.30, with a high forecast of $32.30 and a low forecast of $32.30. The average price target represents a 23.75% upside from the last price of $26.10.

Buy

The current consensus among 3 investment analysts is to buy stock in Burning Rock Biotech.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/17/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/15/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/15/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/13/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/11/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/9/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/10/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/10/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/13/2020Bank of AmericaInitiated CoverageBuy$32.30Low
i
7/7/2020Morgan StanleyInitiated CoverageOverweightHigh
i
7/7/2020CowenInitiated CoverageOutperformHigh
i
(Data available from 5/10/2016 forward)
Burning Rock Biotech logo
Burning Rock Biotech Limited primarily develops and provides cancer therapy selection tests in the People's Republic of China. The company primarily offers 12 next-generation sequencing-based cancer therapy selection tests applicable to a range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoScreen IO, a pan-cancer test for tissue samples; OncoCompass IO, the corresponding test for liquid biopsy samples; OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC; ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and OncoScreen ParpMatch and OncoCompass ParpMatch to target critical genes associated with homologous recombination deficiency. The company also offers LungCore for lung cancer, ProstrateCore for prostrate cancer, BreastCore for breast cancer, LymphPlasma for lymphomas, and ThyroCare for thyroid cancer. In addition, it has development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; and licensing agreement with Oncocyte Corporation to in-license DetermaRx, a risk stratification test for early stage lung cancer patients in China. Burning Rock Biotech Limited has collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, Sino Biopharm, CStone and BeiGene. The company was founded in 2014 and is headquartered in Guangzhou, China.
Read More

Today's Range

Now: $26.10
$26.10
$26.75

50 Day Range

MA: $28.26
$23.50
$30.60

52 Week Range

Now: $26.10
$18.64
$39.75

Volume

238 shs

Average Volume

347,844 shs

Market Capitalization

$2.73 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Burning Rock Biotech?

The following Wall Street research analysts have issued reports on Burning Rock Biotech in the last year: Bank of America Co., Cowen Inc, Morgan Stanley, and Zacks Investment Research.
View the latest analyst ratings for BNR.

What is the current price target for Burning Rock Biotech?

1 Wall Street analysts have set twelve-month price targets for Burning Rock Biotech in the last year. Their average twelve-month price target is $32.30, suggesting a possible upside of 23.8%. Bank of America Co. has the highest price target set, predicting BNR will reach $32.30 in the next twelve months. Bank of America Co. has the lowest price target set, forecasting a price of $32.30 for Burning Rock Biotech in the next year.
View the latest price targets for BNR.

What is the current consensus analyst rating for Burning Rock Biotech?

Burning Rock Biotech currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe BNR will outperform the market and that investors should add to their positions of Burning Rock Biotech.
View the latest ratings for BNR.

What other companies compete with Burning Rock Biotech?

Other companies that are similar to Burning Rock Biotech include Natera, Invitae, Elekta AB (publ), CareDx, Veracyte, Fulgent Genetics, Genetron, Castle Biosciences, RadNet, Renalytix AI, Personalis, DermTech, Celcuity, Exagen and Centogene.

How do I contact Burning Rock Biotech's investor relations team?

Burning Rock Biotech's physical mailing address is 601 BUILDING 3 STANDARD INDUSTRIAL UNIT2, GUANGZHOU F4, 510005. The company's listed phone number is 86 20 3403 7871. The official website for Burning Rock Biotech is www.brbiotech.com.